News | Breast Imaging | March 18, 2025

Architectural distortions detected by DBT alone with no ultrasound correlate and nonmalignant results on core needle biopsy

Derek L. Nguyen, MD
Duke University School of Medicine


March 13, 2025  — According to research published in the American Journal of Roentgenology (AJR), imaging surveillance may be a safe alternative to surgical excision for architectural distortions (ADs) detected by digital breast tomosynthesis (DBT) alone with no sonographic correlate showing benign pathology without atypia on core needle biopsy (CNB).

“The malignancy rate was 0% for ADs without atypia, versus 20% for ADs with atypia, on CNB,” explained first author Derek L. Nguyen, MD, from the radiology department at Duke University School of Medicine in Durham, NC.

Dr. Nguyen and colleagues’ AJR accepted manuscript included patients with ADs detected by DBT alone with no ultrasound correlate and nonmalignant results on stereotactic CNB with 12 vacuum-assisted 9-gauge cores from July 1, 2020, to December 31, 2023. ADs detected by DBT alone with no ultrasound correlate showing concordant benign pathology or radial scar without atypia on CNB were recommended to undergo 6-month and 12-month diagnostic imaging follow-up before returning to annual screening, whereas those showing atypia (with or without radial scar) on CNB were recommended to undergo surgical excision; however, patients could electively undergo the alternative management option. Nguyen et al. then assessed malignancy rates, considering ADs to be nonmalignant based on results of repeat CNB, surgical excision, or 12-month diagnostic imaging follow-up.

Ultimately, for ADs detected by DBT alone with no ultrasound correlate and nonmalignant results on CNB obtaining 12 vacuum-assisted 9-gauge samples, malignancy rates were 0% (0/94) in the absence of atypia (with or without radial scar), versus 20% (3/15) in the presence of atypia (with or without radial scar), on CNB.

54-year-old woman undergoing breast cancer screening

ARRS
(a) Craniocaudal (CC) view from screening digital breast tomosynthesis (DBT) mammogram shows architectural distortion (AD) (circle) in upper inner position. AD was not detected by digital mammography (not shown). (b) Spot CC view from subsequent diagnostic DBT mammogram shows persistence of AD (circle). No ultrasound correlate was identified (not shown). Core needle biopsy of AD was performed, yielding radial scar without atypia. (c) Postbiopsy mammogram shows cylinder clip (arrow) in appropriate position. Biopsy result was considered concordant, and patient underwent recommended imaging surveillance. (d) Spot CC view from diagnostic mammogram performed 12 months later shows stable appearance of AD (circle).

 

 


Related Content

News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
News | Artificial Intelligence

July 9, 2024 — Lunit, a provider of Artificial Intelligence (AI)-powered solutions for cancer diagnostics and ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Artificial Intelligence

June 26, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced it ...

Time June 26, 2024
arrow
News | MRI Breast

June 12, 2024 — Royal Philips recently announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet ...

Time June 12, 2024
arrow
News | Breast Density

June 6, 2024 — Subsequent rounds of abbreviated breast MRI (AB-MR) screening in patients with dense breasts had lower ...

Time June 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As we flip the page to a new month on our calendars, here is a look at the Top 10 pieces of content viewers were reading ...

Time June 04, 2024
arrow
News | FDA

May 22, 2024 — The U.S. Food and Drug Administration (FDA) has issued a recall of the Hologic Inc. BioZorb marker due to ...

Time May 22, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a provider of Artificial intelligence (AI)-powered solutions for cancer diagnostics and ...

Time May 22, 2024
arrow
News | Radiology Business

May 6, 2024 — ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief ...

Time May 06, 2024
arrow
Subscribe Now